Entire cohort | Women | Men | ||||
---|---|---|---|---|---|---|
HR (95% CI) | n(events) | HR (95% CI) | n(events) | HR (95% CI) | n(events) | |
BRAF status-MSS tumours (unadjusted) | ||||||
Wild-type | 1.00 | 384 (135) | 1.00 | 194 (64) | 1.00 | 190 (71) |
Mutated | 2.36 (1.44–3.86) | 29 (18) | 1.73 (0.83–3.61) | 16 (8) | 3.46 (1.78–6.74) | 13 (10) |
BRAF status-MSI tumours (unadjusted) | ||||||
Wild-type | 1.00 | 28 (4) | 1.00 | 16 (2) | 1.00 | 12 (2) |
Mutated | 1.68 (0.53–5.36) | 43 (10) | 2.15 (0.46–10.12) | 31 (8) | 1.03 (0.14–7.31) | 12 (2) |
BRAF status-MSS tumours (adjusted) | ||||||
Wild-type | 1.00 | 343 (118) | 1.00 | 169 (54) | 1.00 | 174 (64) |
Mutated | 1.80 (0.98–3.28) | 23 (14) | 1.37 (0.56–3.35) | 14 (7) | 4.91 (1.99–12.12) | 9 (7) |
BRAF status-MSI tumours (adjusted) | ||||||
Wild-type | 1.00 | 27 (4) | - | - | - | - |
Mutated | 3.24 (0.39–26.92) | 40 (8) | - | - | - | - |